Noveome Biotherapeutics INC
Doing business as Stemnion INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersPittsburgh, PA
US patents50
SAM.gov UEID35WXDLB8K59
CAGE code47YW6
Incorporated inDE
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
50 US patents granted 2011–2024, 1 of them in the five years to SEP 2025.
Pharmaceuticals 47Medical technology 3
- Treatment of systemic inflammatory responsesUS 12,121,546 · granted OCT 22, 2024
- Methods for treating traumatic brain injury with amnion-derived cellular cytokine solution (ACCS) or amnion-derived multipotent progenitor (AMP) cellsUS 10,286,015 · granted MAY 14, 2019
- Treatment of diseases and conditions caused by increased vascular permeabilityUS 9,980,987 · granted MAY 29, 2018
- Interproximal drug delivery deviceUS 9,802,010 · granted OCT 31, 2017
- Medical deviceUS 9,662,417 · granted MAY 30, 2017
Newest 5 shown · Granted to Stemnion, INC., Noveome Biotherapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Noveome Biotherapeutics INC | Pittsburgh | PA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


